The superiority of carfilzomib vs bortezomib in triplet therapy was compared in newly diagnosed multiple myeloma ineligible for immediate transplantation.
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
The cytogenetic abnormality was linked to inferior overall survival.
Patients with myeloma should receive 2 doses of the trivalent or quadrivalent vaccine influenza vaccine and vaccinations should continue annually.
The approval was based on data from the phase 3 CANDOR study and the phase 1b EQUULEUS trial.
Patients who relapsed 3 years or later after first transplant had significantly better progression-free and overall survival compared with those who relapsed earlier.
Increased odds of adverse outcomes seen for Hispanic/Latinos, African-American Blacks vs white patients.
A percentage of newly diagnosed patients had disease with lower genomic instability.
Oncopeptides will seek accelerated approval from the FDA after melflufen demonstrates a manageable safety profile.
The phase 3 IFM/DFCI 2009 trial investigators used WGS to determine genomic markers of long-term survival in patients with newly diagnosed MM.
The combination of carfilzomib, dexamethasone, and daratumumab significantly prolonged PFS in patients with relapsed or refractory multiple myeloma.
Patients with multiple myeloma on dialysis who are undergoing autologous stem cell transplantation are at an increased risk for inpatient mortality.
The FDA issued a clinical hold for a trial evaluating a universal CAR T-cell product in patients with relapsed or refractory multiple myeloma after 1 patient died.
MM cells expressing high levels of migration inhibitory factor may have poorer responses to proteasome inhibitors, resulting in adverse patient outcomes.
For patients with initial myeloma cast nephropathy, renal response rates did not significantly vary after doublet vs triplet bortezomib-based treatments.
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
Ixazomib, lenalidomide, and dexamethasone are all oral agents and each one has been approved by the FDA in the setting of multiple myeloma.
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
Researchers presented initial results from an ongoing, phase 3, randomized study of once-weekly SVd vs twice-weekly Vd after 1 to 3 prior anti-multiple myeloma regimens.
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
Findings from this study support use of serial MRD monitoring during lenalidomide maintenance therapy to identify patients likely to benefit from prolonged treatment.
Researchers reported significant improvements in 5-year relative survival among older patients with multiple myeloma who were diagnosed from 1982 to 2017.
Higher graft CD34+ cell content is linked to improved platelet and neutrophil recovery after high-dose therapy.
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
Guidance is provided regarding possible treatment plan alterations for older patients with multiple myeloma based on COVID-19 infection risk.
Darzalex Faspro is a new subcutaneous formulation that contains daratumumab, a CD38-directed cytolytic antibody, with hyaluronidase, an endoglycosidase.
Differential effect seen by race, with significantly lower OS for white but not African-American patients.
Previous mostly retrospective/observational studies evaluated low-dose aspirin administered once daily in the setting of ET. In this study, the more frequent dosing was found optimal.
The SKY92 MMprofiler assay evaluates the expression of 92 multiple myeloma-related genes.
Investigators found that SC administration of daratumumab was noninferior to IV administration, and patient satisfaction appeared to be higher in the SC group.
An expanding range of treatment options in the past decade has led to greater long-term survival in patients with multiple myeloma.
In recent years, the NCCN has updated its clinical practice guidelines to include MRD assessment for MM, ALL, and CLL.
While HLA-identical sibling or unrelated donors were previously critical for successful transplantation, increased genomic heterogeneity across populations have heightened the need for alternatives.
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Prior therapy with lenalidomide and shorter disease history were found to correlate with poorer outcomes.
The FDA has approved Sarclisa (isatuximab-irfc; Sanofi), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
For patients with newly diagnosed multiple myeloma, a less frequent dosing regimen of bortezomib may elicit a similar clinical response.
In this study, 1 of the criteria for defining intermediate- or high-risk smoldering multiple myeloma was clonal bone marrow plasma cells between 10% and less than 60%.
Patients who were enrolled in clinical trials that employed a total therapy protocol had a lower early mortality rate compared with patients not on a total therapy protocol.
For biologically effective dose ≤28 Gy
10, small but significant increase seen in reirradiation rates
Researchers compared the monoclonal immunoglobulin rapid accurate measurement and matrix-assisted laser desorption/ionization-time of flight assays.
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
Progression-free survival, overall survival, and percentage of patients who achieved very good partial response or better were similar between both treatment groups.